Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Healthcare Medical Devices
Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

VentriPoint Diagnostics Ltd > Good news 👀 Ventripoint article 😎 The Globe and Mail 🚀🚀
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(91)
•••
Comment by jopatcloon Sep 26, 2024 7:15am
39 Views
Post# 36241670

RE:Good news 👀 Ventripoint article 😎 The Globe and Mail 🚀🚀

RE:Good news 👀 Ventripoint article 😎 The Globe and Mail 🚀🚀 Pandor  ...Now that V4.0 is ok for Canada ! and this 

Good news Ventripoint article The Globe and Mail

Maybe we will have some good news for sales here in Canada ?

and on Linkedin very good news Ascend Cardiovascular NOW INTRODUCING: GEN3ECHO the BEST automation and analysis on the planet:
On website Ascend Cardiovascular https://ascendcv.com/
= 1,185 Hospitals
= 27,631,056 Procedure reports
= 49,506 Users
= 693 Health systems how many The BEST automation and analysis on the PLANET GEN3EHO
Now that V4.0 is ok for Canada It would be perfect to have FDA 4.0 before BSEcho 2024!
Remenber Where has Hugh been lately Hugh in London maybe news Collaborations or Partnerships ? FDA V4.0 and Sales at any time now Insiders know!
Image preview

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities